Jennifer Lachey, Chief Scientific Officer at Keros Therapeutics, Inc. (KROS), sold 10,041 shares at $61.37 ($630K) on 2022-04-11, disclosed to the SEC on 2022-04-13.
Open-market sale of $630k KROS by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $61.37 | 1,417 | $87K | 13.8% |
| 2 | $61.37 | 1,417 | $87K | 13.8% |
| 3 | $62.32 | 1,009 | $63K | 10.0% |
| 4 | $62.32 | 1,009 | $63K | 10.0% |
| 5 | $63.50 | 2,315 | $147K | 23.4% |
| 6 | $63.50 | 2,315 |
| $147K |
| 23.4% |
| 7 | $64.15 | 559 | $36K | 5.7% |
| Total | $62.70 avg | 10,041 | $630K | 100% |
| Filing → |
| KROS | SELL | 2022-05-13 | $362K | — | Filing → |
| KROS | SELL | 2022-04-06 | $477K | — | Filing → |
| KROS | SELL | 2022-03-15 | $197K | — | Filing → |